LAM focuses on Chinese diabetic ulcer market:
This article was originally published in Clinica
Executive Summary
LAM Pharmaceutical is to explore distribution and strategic alliance opportunities in China with Benchmark Global Capital Group's Chinese subsidiary, one of the leading US-based investment and consulting firms in China. Lewiston, New York-based LAM develops the IPM wound gel, for the management of certain skin ulcers and wounds. Benchmark notes that, although China has the world's largest diabetic population, with almost 65 million patients, there are currently no effective products for treating diabetic wounds and ulcers on the Chinese market.